● Recruiting

Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)

Condition: Coronary Microvascular Dysfunction · Coronary Microvascular Disease · Sponsor: VahatiCor, Inc.

PhaseNA

Planned participants30

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.

This description comes directly from the study's public registry record.

Talk to the study team

Madison Kenley, BS · +1(801)552-8383 · mkenley@vahaticor.com

Janie Mandrusov, PhD · clinicalaffairs@vahaticor.com

Always discuss trial participation with your own doctor first.

Locations (3)

University Medical Center Utrecht	Utrecht, Netherlands	Recruiting
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu	Warsaw, Poland	Recruiting
Hospital Clínic Barcelona	Barcelona, Spain	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06991322